Drug Policy Watch · State Brief 2026

Delaware

Snapshot (structured)

Adult-use cannabis: Legal (2023); retail sales live since August 1, 2025
Medical cannabis: Legal (2011); expanded by HB 285 (2024)
Home grow: Prohibited for both adult-use and medical users
Intoxicating hemp / hemp THC: Effectively restricted to licensed cannabis channels; THC beverage regulation (HB 373, $0.50 per container tax) passed the General Assembly in 2026 and awaited the governor's signature as of mid-July
Psychedelics: Illegal; no enacted decriminalization or therapeutic-access framework
Broad decriminalization: Partial; small-amount cannabis decriminalized (2015); HS 1 for HB 252 (2026) would make public personal-use possession of any controlled substance a civil violation
Harm reduction: Robust; syringe services, free naloxone, fentanyl and xylazine test strips
Governor (party): Matt Meyer (Democrat)
Legislature control: Democratic trifecta with veto-proof supermajorities in both chambers
Citizen ballot initiatives allowed: No
Enclosure pressure score: 3/5

Cannabis

Delaware legalized adult-use cannabis in April 2023, when then-Governor John Carney allowed HB 1 and HB 2 to become law without his signature, making the state the 22nd to legalize. HB 1 legalized possession of up to one ounce by adults 21 and over; HB 2 (the Delaware Marijuana Control Act) created the regulated, taxed market. Both were sponsored by Rep. Ed Osienski in the House, with Sen. Trey Paradee leading in the Senate. (Sources: housedems.delaware.gov, mpp.org, greenstate.com.)

Medical cannabis has been legal since 2011. In 2024, HB 285 (sponsored by Rep. Ed Osienski) expanded the medical program and took effect immediately. (Source: senatedems.delaware.gov, mpp.org.)

Home cultivation is not allowed for either adult-use or medical users. (Source: greenstate.com, mpp.org.)

Market structure. Retail adult-use sales began August 1, 2025. The launch ran through the state's existing medical operators first: 13 medical dispensaries ("compassion centers," run by six vertically integrated operators) paid $100,000 each for conversion licenses and were the only stores open at launch under a "first-mover" arrangement enabled by HB 408 (signed July 17, 2024). The state has authorized 30 new adult-use retail licenses (15 open, 15 social equity) plus additional cultivation, manufacturing, and testing licenses awarded by lottery in late 2024. As of the most recent reporting (early 2026), the 16 conditional retail licensees that are not converted medical operators had not yet opened, so the converted compassion centers remained the only operating storefronts. (Sources: news.delaware.gov, cannabisbusinesstimes.com, whyy.org.)

Adult-use sales carry a 15% excise tax. Early performance fell well short of projections: about $29.3 million in sales over the first seven months (roughly $4.2 million per month), versus the former commissioner's 2023 projections that implied a far larger market. That run rate annualizes to a little over $50 million in sales and about $7.5 million in tax revenue, trailing neighbors New Jersey and Maryland. Opening weekend was about $903,000; the first month was about $7.3 million. (Sources: whyy.org, marijuanaretailreport.com, news.delaware.gov.)

Key 2026 actions: see Active legislation. The headline items are HB 252 / HS 1 (public-use penalty downgrade), SB 75 (county local control over retail stores), and HB 271 (establishment spacing).

Hemp

Delaware effectively restricts intoxicating hemp-derived THC products to its licensed cannabis program. Trade and explainer sources indicate that delta-8, delta-10, THCA, HHC, THCP, and similar intoxicating cannabinoids are either prohibited or limited to licensed dispensary channels, with the operating rule being that an intoxicating product must come from a licensed Delaware dispensary to be legal. This characterization comes from secondary/commercial sources rather than a single cited statute, so treat the precise scope as somewhat uncertain and verify against the Delaware Code before relying on it. (Sources: themarijuanaherald.com, burningdaily.com, delawarestatecannabis.org.)

In 2025, Rep. Debra Heffernan (D-Bellefonte) introduced legislation to bring the unregulated market for THC-infused beverages and edibles under state control. The bill, reported as HB 98, would have routed THC beverages exclusively through Delaware's three-tier alcohol system: sales only at specially licensed liquor stores, a $1-per-container tax, a 10mg THC cap per drink, regulation by the Office of the Alcohol Beverage Control Commissioner, distribution through the state's licensed liquor distributors, and lab testing. After backlash over the impact on small hemp retailers, Heffernan tabled/withdrew the measure in June 2025 and signaled it would return in a later session. (Sources: delawarepublic.org, spotlightdelaware.org, marijuanamoment.net, cannabisregulations.ai.)

Federal exposure and the November 12, 2026 deadline. Congress enacted a narrowed federal definition of "hemp" that effectively bans most intoxicating hemp-derived THC products nationwide, with the new provisions taking effect November 12, 2026. After that date, products excluded from the revised hemp definition could face enforcement under the federal Controlled Substances Act. Because Delaware already channels intoxicating cannabinoids toward its licensed cannabis program, the federal change reinforces rather than reverses the state's posture, though it raises the enforcement stakes for any gray-market hemp retail still operating. Note that rollback proposals were already circulating in Congress as of late 2025, so the federal effective date is not fully settled. (Sources: scarincihollenbeck.com, regulatoryoversight.com, wilsonelser.com, themarijuanaherald.com.)

Psychedelics

Delaware has not decriminalized psilocybin or other psychedelics and has no enacted therapeutic-access program. Psilocybin mushrooms remain illegal. National trackers covering the 2025 to 2026 psychedelic-policy wave do not list Delaware among the states with active decriminalization or regulated-access bills, and this research did not surface a confirmed 2026 Delaware psychedelics bill. Treat the absence as "no confirmed activity" rather than a definitive negative; check the Delaware General Assembly site for any late filings. (Sources: recovered.org, worldpopulationreview.com, psychedelicalpha.com.)

Broader drug policy

Decriminalization. Delaware decriminalized possession of small amounts of cannabis in 2015 and legalized adult possession up to one ounce in 2023. In the 2026 session, the most significant broader-drug-policy move is HS 1 for HB 252: as voted out of committee (reported March 10, 2026) the substitute would make use or consumption of a personal-use quantity of any controlled substance in a public place a civil violation rather than a misdemeanor, with fines up to $50 for a first offense and up to $100 for later offenses. The substitute dropped the original bill's coverage of use inside a moving vehicle. The original HB 252 was framed around marijuana; the substitute broadened it to controlled substances generally, which is a notable expansion. (Sources: themarijuanaherald.com, marijuanamoment.net, legis.delaware.gov, inquirer.com.)

Harm reduction. Delaware runs a comparatively strong harm-reduction program. Naloxone, fentanyl test strips, and syringe services are available free and anonymously, including via vending machines, through Brandywine Counseling locations statewide. The Division of Public Health began bundling fentanyl test strips into naloxone kits in 2022, and in June 2023 the state launched what was reported as the nation's first combined fentanyl-and-xylazine test strip distribution pilot. Delaware law exempts drug-checking equipment and other paraphernalia from criminal liability when obtained from a syringe exchange. (Sources: helpisherede.com, news.delaware.gov, delawarepublic.org, dhss.delaware.gov.)

Sentencing and expungement. See Equity and expungement below.

Overdose and treatment policy. The state's harm-reduction infrastructure is coordinated through the Division of Public Health and the "Help Is Here Delaware" portal, with opioid-settlement and overdose-prevention resources channeled to test-strip and naloxone distribution. (Source: helpisherede.com.)

Political landscape

Governor: Matt Meyer (Democrat), in office since January 21, 2025; previously New Castle County Executive. (Sources: ballotpedia.org, en.wikipedia.org.)

Legislature: Democrats hold both chambers with veto-proof supermajorities. Following the 2024 elections the Senate was 15-6 Democratic and the House 27-14 Democratic, and Delaware entered 2026 as one of a small number of Democratic trifectas with supermajorities in both chambers. (Source: ballotpedia.org.) The 2026 session is the second leg of the 153rd General Assembly; bills not passed by June 30 die and must be refiled in 2027. (Source: spotlightdelaware.org.)

Reform champions: Rep. Ed Osienski and Sen. Trey Paradee were the architects of legalization (2023) and remain central cannabis voices. Rep. Eric Morrison and Sen. Marie Pinkney are leading the 2026 public-use decriminalization effort (HB 252 / HS 1). (Sources: housedems.delaware.gov, themarijuanaherald.com.)

Opponents / friction points: This research did not surface a single named, organized legislative opponent of cannabis reform in 2026. The most concrete recent friction was over hemp THC beverage regulation, where small hemp retailers pushed back against routing sales through liquor stores, prompting Rep. Heffernan to table HB 98. Specific named opponents are unconfirmed.

Key committees for drug-policy bills are unconfirmed in this brief; check the bill pages on legis.delaware.gov for committee assignments.

Ballot initiatives

Delaware does not allow citizen-initiated ballot measures; policy change runs through the General Assembly. There are accordingly no pending citizen cannabis, psychedelic, or drug-policy ballot measures for 2026. (This reflects Delaware's long-standing lack of an initiative process; no source in this research indicated any change.)

Equity and expungement

Social-equity licensing. The Marijuana Control Act reserves a substantial share of licenses for social equity applicants: 15 of the 30 new adult-use retail licenses are social equity. Social equity applicants pay a discounted $1,000 application fee and biennial license fees at 40% of the open-license rate, and must maintain a labor peace agreement (per § 1337). Microbusiness licensees pay a $3,000 application fee and also benefit from the 40% reduced license cost. (Sources: omc.delaware.gov, delawarecannabispolicy.org.)

A real-world equity concern: reporting indicated that outside consultants targeted Delaware's social equity cannabis applicants, in some cases maneuvering to capture the licenses or value those applicants won, which undercuts the program's intent. (Source: whyy.org.)

Expungement. Delaware has layered cannabis-record relief. A 2018 law (reported as SB 197) let people with a single conviction for possessing up to an ounce automatically qualify to clear their record; a 2019 law allowed expungement of a single cannabis misdemeanor after five years and a single cannabis felony after seven years. Under the Clean Slate law, automatic expungement for mandatory-eligible offenses, including misdemeanor cannabis possession and certain old drug felonies, began August 1, 2024. The specific bill numbers (SB 197, the 2019 measure, and Clean Slate) come from secondary sources and should be confirmed against the Delaware Code. (Sources: mpp.org.)

Market and barriers

Cannabis tax: 15% excise tax on adult-use sales. (Source: whyy.org, news.delaware.gov.)

License application fees (non-refundable; licenses valid 2 years), per the Office of the Marijuana Commissioner: - Retail (open): $5,000 application, $10,000 license; (social equity): $1,000 application, $4,000 license. - Manufacturing (open): $5,000 / $10,000; (social equity or microbusiness): $1,000 or $3,000 application, $4,000 license. - Testing (open): $5,000 / $10,000; (social equity): $1,000 / $4,000. - Cultivation (open): $5,000 application; license cost by size tier ($2,500 to $10,000); (social equity): $1,000 application; (microbusiness): $3,000 application; both at 40% of the open license cost. (Source: omc.delaware.gov licensing cost page.)

Medical-to-adult-use conversion: existing compassion centers paid $100,000 per conversion license to open for adult-use sales. (Source: whyy.org.)

License caps and counts. The framework authorizes 30 adult-use retail licenses (15 open, 15 social equity), in addition to the six vertically integrated medical operators running 13 compassion centers. Late-2024 lotteries awarded roughly 110 to 125 licenses across cultivation, manufacturing, testing, and retail categories out of large applicant pools (for example, 529 eligible applicants for the 15 open retail licenses; 729 applicants in the October cultivation/manufacturing/testing/social-equity round). As of early 2026, 16 conditional non-medical retail licensees had not yet opened. Exact current operating counts shift as conditional licensees build out, so verify against OMC. (Sources: omc.delaware.gov, cannabisbusinesstimes.com, whyy.org.)

Capital and residency requirements: not confirmed in this research; check OMC regulations.

Enclosure read

Delaware sits in the middle of the consolidation spectrum. The strongest enclosure signal is the launch design: the only stores allowed to open on day one were the six vertically integrated medical operators (13 compassion centers), each paying a $100,000 conversion fee, giving incumbent multi-license operators a months-long head start over the lottery winners, who as of early 2026 still had not opened. That first-mover advantage concentrates early revenue and brand position with the established medical players.

Pushing the other direction: a hard 30-license retail cap split evenly between open and social-equity applicants, microbusiness and social-equity fee discounts, and a license-lottery model rather than pure capital competition all constrain runaway consolidation and reserve room for smaller and equity entrants. The hemp THC beverage fight also showed the legislature willing to pause a bill that would have handed an entire product category to liquor distributors and shut out small hemp shops, which cut against enclosure.

Working against the little guy: the home-grow ban removes the fully decentralized option, the social-equity applicant pool was reportedly targeted by predatory consultants, and weak early sales make it harder for thinly capitalized new entrants to survive long enough to open. Net read: a capped, equity-flavored market that nonetheless front-loaded advantage to vertically integrated incumbents. That balance supports a score of 3 out of 5.

Enclosure pressure score: 3/5.

What to watch next

November 12, 2026: federal narrowed hemp definition takes effect, with enforcement exposure for non-licensed intoxicating hemp products; watch for congressional rollback efforts that could move this date.
June 30, 2026: end of the second leg of the 153rd General Assembly; bills not passed (including HB 252 / HS 1) die and must be refiled in 2027.
HB 252 / HS 1: whether the broadened controlled-substance public-use civil-violation bill clears the floor before adjournment.
HB 373, the successor to HB 98, regulates THC-infused beverages ($0.50 per container tax) and passed the General Assembly in 2026; watch for the governor's signature.
Openings of the 16-plus conditional non-medical retailers and the 30 new retail licensees; monthly sales trajectory after a weak first seven months (about $29.3 million).
The Delaware General Assembly reconvened for 2026 on January 13, 2026.

Regulators

Office of the Marijuana Commissioner (OMC), a division of the Department of Safety and Homeland Security: licenses and regulates adult-use and medical cannabis. Commissioner: Joshua Sanderlin, a cannabis regulatory attorney appointed by Gov. Meyer and confirmed effective May 16, 2025, succeeding founding commissioner Robert (Rob) Coupe, who resigned in January 2025. (Sources: omc.delaware.gov, delawarepublic.org, news.delaware.gov.)
Office of the Alcohol Beverage Control Commissioner: would regulate THC beverages under the HB 98 approach; that bill was superseded by HB 373, which passed the General Assembly in 2026 and awaits the governor's signature.
Division of Public Health (DHSS): oversees harm-reduction, naloxone, and test-strip distribution.
Hemp cultivation falls under the Delaware Department of Agriculture (general hemp program; not separately confirmed in this research).

Federal exposure (2026)

Rescheduling and 280E. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, ending the Section 280E tax penalty for that medical category, while recreational cannabis stays Schedule I. Delaware sits in an unusual spot because its adult-use market launched in 2025 entirely through converted medical compassion centers: the same six vertically integrated operators run both the medical compassion centers and, under HB 408 conversion licenses, the adult-use storefronts. The narrow order gives these operators 280E relief on their medical cannabis activity, but their adult-use sales remain Schedule I and fully exposed to 280E, which disallows ordinary business deductions. For dual-license operators that is an open allocation problem: medical and adult-use revenue, inventory, and overhead must be separated cleanly enough to claim the medical relief without sweeping in non-deductible recreational activity. Because Delaware's market is so heavily weighted toward adult-use sales running through these converted centers, the practical relief is partial, the recreational side of the same companies sees no change, and the new lottery retailers (open and social equity) that have not yet opened are recreational-only and get nothing from the order. Schedule III does not legalize, does not authorize interstate commerce, and does not reach state recreational businesses, so Delaware's market structure and rules are unchanged. The broader DEA rescheduling hearing that opened June 29, 2026 (and may slip to 2027) is the only path that would extend relief to the recreational side; until it concludes, Delaware's adult-use operators stay on Schedule I. (Sources: foleyhoag.com, beneschlaw.com, lexology.com, 365cannabis.com.)

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD) narrows the federal hemp definition to a total-THC standard of about 0.4 mg THC per container, recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the delay bill H.R.7010 was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban. Delaware does not run an open intoxicating-hemp market: by state posture it channels intoxicating cannabinoids such as delta-8, delta-10, THCA, HHC, and THCP toward its licensed dispensary system, with the operating rule being that an intoxicating product must come from a licensed Delaware dispensary to be legal (note this characterization rests on secondary sources and the precise statutory scope is somewhat uncertain). The practical effect of the federal cliff is therefore reinforcement rather than reversal: Delaware was already pushing intoxicating hemp into licensed channels, and the federal change removes the interstate hemp supply line and raises Controlled Substances Act enforcement stakes for any gray-market hemp retail still operating in the state. The HB 98 THC-beverage framework (Rep. Debra Heffernan, D-Bellefonte) became more salient because the federal cliff strengthens the case for a state-run channel even as it shrinks the legal hemp-beverage category that bill assumed; its successor, HB 373, passed the General Assembly in 2026 and awaits the governor's signature. Rollback proposals were circulating as of late 2025, so the effective date is not fully settled. (Sources: scarincihollenbeck.com, regulatoryoversight.com, wilsonelser.com, themarijuanaherald.com.)

Banking. SAFER Banking remains stalled in the Republican Congress, so Delaware operators still face limited access to deposit accounts, lending, and card payments, and continue to run heavily on cash. This lands hard given Delaware's slow, low-revenue launch: about $29.3 million in sales over the first seven months, a run rate that annualizes to a little over $50 million. Thin margins plus no normalized banking plus continued 280E on the recreational side make it harder for the not-yet-open lottery and social-equity retailers, which tend to be thinly capitalized, to survive long enough to open and scale. The converted incumbents are better positioned to absorb cash-handling and financing friction than new entrants.

Psychedelics. The April 18, 2026 federal executive order plus FDA priority vouchers fast-track FDA review of psilocybin, MDMA, and ibogaine, but those substances remain Schedule I with no approval yet, and conditional rescheduling triggers only on FDA approval. Delaware has no enacted decriminalization or therapeutic-access framework and this research surfaced no confirmed 2026 Delaware psychedelics bill (treat as no confirmed activity rather than a definitive negative; check legis.delaware.gov for late filings). The practical effect: Delaware has no state-level pathway of its own, so any near-term change for Delaware patients would come only through the federal FDA route, not state law. (Sources: psychedelicalpha.com, recovered.org.)

Harm reduction. This is Delaware's sharpest federal exposure. SAMHSA guidance issued April 24, 2026 (building on July 2025 guidance under the Ending Crime and Disorder on America's Streets executive order) bars federal grant funds from buying fentanyl test strips, clean syringes, sterile water, and related drug-checking supplies, including xylazine test strips; naloxone is still supported. Delaware runs a comparatively strong harm-reduction program built on exactly the supplies the guidance now defunds: free and anonymous fentanyl test strips bundled into naloxone kits since 2022, syringe services, and a combined fentanyl-and-xylazine test strip pilot launched in 2023, distributed through Brandywine Counseling and coordinated by the Division of Public Health. To the extent these programs rely on federal SAMHSA dollars, the state must either backfill with state or opioid-settlement funds or scale back distribution of test strips, syringes, and sterile water; naloxone supply is insulated. The xylazine test strip program is especially exposed because the guidance names xylazine strips specifically. (Sources: naco.org, statnews.com, ssdp.org, helpisherede.com, news.delaware.gov, delawarepublic.org.)

Patient access and rights

This section covers what Delaware law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Delaware enacted a Ryan's Law protection in 2026. Senate Bill 226 lets a terminally ill patient use medical cannabis in a health care facility, but it does not take effect until May 21, 2027, so it is not yet in force. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending.

Broader protections: Delaware is the strongest state in this group, and these protections are already in force, having been part of the Delaware Medical Marijuana Act since 2011. Under Title 16, Section 4905A, a registered patient is protected across all six areas: employment (an employer may not discriminate based on patient status unless federal law requires it), housing (a landlord may not refuse to lease on that basis), school enrollment, parental and custody rights (no presumption of neglect for conduct the Act allows, absent clear evidence of danger to the child), and medical care including organ transplants (authorized use is treated as the equivalent of any other prescribed medication).

Out-of-state patients: Delaware offers a temporary visiting-patient path rather than full reciprocity; verify at the point of travel.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right or employment, housing, custody, transplant, or school protection; the protections and limits above are creatures of Delaware law, not federal law.

Sources: Delaware's patient protections, Title 16, Section 4905A; the hospital-access law, Senate Bill 226 (2026).

Analysis: the enclosure read in depth

Who is fenced out and who consolidates. Delaware's adult-use market was built on a deliberate incumbency advantage, and the 2026 federal levers deepen it. The only stores open at launch and through early 2026 are the six vertically integrated operators that converted their medical compassion centers under HB 408, each paying a $100,000 conversion fee. The April 2026 Schedule III order hands those same operators a federal tax benefit, 280E relief, but only on their medical cannabis activity, the one line of business that new lottery and social-equity retailers do not have. New entrants are recreational-only, so they get no 280E relief, no banking normalization (SAFER stalled), and they enter a market that is both slow (about $29.3 million in seven months) and already occupied by branded incumbents with a months-long head start. The federal layer thus rewards precisely the structural position Delaware's launch design already favored: the dual medical-plus-adult-use operator. That is the core enclosure dynamic, a state head start for incumbents reinforced by a federal tax break that only incumbents can fully use.

The state-plus-federal interaction. On hemp, the state and federal moves point the same direction. Delaware already channels intoxicating hemp toward licensed dispensaries, and the November 12, 2026 federal cliff recriminalizes most intoxicating hemp products nationally; together they fence out small hemp shops and the informal hemp-THC market, pushing whatever demand survives into the licensed cannabis system the incumbents dominate. This mirrors the national pattern in the federal context, an enclosure that favors large incumbents and pharma while fencing out small and informal actors and hemp. The HB 98 beverage bill, which small hemp retailers fought because it would have routed THC drinks through liquor distributors, sat at this seam: the federal cliff strengthens the rationale for a state channel while shrinking the legal hemp category. Its successor, HB 373, which regulates THC-infused beverages with a $0.50 per container tax, passed the General Assembly in 2026 and awaits the governor's signature.

Where commons counter-moves are present or absent. Delaware retains several genuine counterweights, which is why the score is not higher. The retail license cap is a hard 30, split evenly between open and social-equity applicants; social-equity and microbusiness applicants get reduced fees (a $1,000 application and license fees at 40 percent of the open rate) and licenses are awarded by lottery rather than pure capital competition; and the legislature showed it would pause a bill (HB 98) that threatened to hand an entire category to liquor distributors. The 2026 HS 1 for HB 252 public-use civil-violation bill, broadened to all controlled substances, points toward decriminalization rather than enclosure. But the counter-moves are partly hollowed out: home grow is banned for both medical and adult-use users, removing the fully decentralized option that is the strongest commons move available to a state; predatory consultants reportedly targeted social-equity applicants, capturing license value the program meant to distribute; and the equity retailers most likely to widen participation are exactly the ones most exposed to no-280E, no-banking, slow-sales pressure. On harm reduction, the SAMHSA defunding is a federal enclosure of the public-health commons, and the only counter-move available is state or settlement backfill, which Delaware has the infrastructure but not guaranteed funding to sustain.

What to watch and the score. Watch the broader DEA rescheduling hearing (opened June 29, 2026, possibly slipping to 2027), which is the only lever that would extend 280E relief to the recreational side and partially level the incumbent advantage; the actual openings of the 16-plus conditional non-medical retailers and the 30 lottery licensees, which is the real test of whether the equity-flavored cap delivers; any hemp rollback in Congress before November 12, 2026; a successor to HB 98; and whether Delaware backfills SAMHSA-defunded harm-reduction supplies. Net: the state design front-loads advantage to vertically integrated incumbents while preserving a capped, equity-flavored structure, and the 2026 federal levers (medical-only 280E relief, stalled banking, a hemp cliff that funnels demand into the licensed system, and harm-reduction defunding) all tilt toward the same incumbents and against small, informal, and thinly capitalized actors. The federal layer pushes Delaware toward more enclosure, but the surviving state counterweights (the cap, equity set-asides, lottery allocation, decriminalization momentum) keep it from the high end. That balance supports the existing score of 3 out of 5.

Active legislation (2026)

This list is not exhaustive. For the full and current set of bills, use the live trackers: LegiScan Delaware (https://legiscan.com/DE), the Delaware General Assembly (https://legis.delaware.gov/).

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HB 252 / HS 1	Downgrades public personal-use possession/consumption of a controlled substance from a misdemeanor to a civil violation ($50 first / $100 later); HS 1 dropped the moving-vehicle provision	House	HS 1 voted out of committee, on Ready List (reported March 10, 2026)	Rep. Eric Morrison (D), prime; co-sponsors incl. Rep. K. Johnson (D), Rep. Berry (D); Sens. Marie Pinkney (D), David Sokola (D), Bryan Townsend (D), Elizabeth Lockman (D)
SB 75	Local control of retail marijuana stores by counties (amends Title 4)	Senate	Passed both chambers. Update, July 18, 2026: enacted July 1, 2026 via veto override. (source)	Unconfirmed (see LegiScan; https://myreptracker.com/delaware/bills/de-153rd-general-assembly-2025-2026-sb-75)
HB 271	Marijuana establishment spacing requirements (amends Title 4)	House	Signed June 24, 2026. (source)	Unconfirmed
HB 98 (2025)	THC-infused beverage regulation via the three-tier alcohol system	House	Superseded by HB 373 (2026), which regulates THC-infused beverages ($0.50/container tax) and passed the General Assembly. (source)	Rep. Debra Heffernan (D-Bellefonte)

Sponsor and status details for SB 75 and HB 271 were not fully confirmed in this research; the linked trackers carry the authoritative record. The HB 252 sponsor and co-sponsor list above is drawn from secondary reporting and should be confirmed against the bill page (https://legis.delaware.gov/BillDetail?LegislationId=142924).

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →